Literature DB >> 9603351

The effects of dexamethasone immunosuppression on turkey osteomyelitis complex in an experimental Escherichia coli respiratory infection.

G R Huff1, W E Huff, J M Balog, N C Rath.   

Abstract

Six hundred male turkeys were maintained in floor pens for 5 wk at which time half of the birds were given three intramuscular injections of 2 mg/kg BW of dexamethasone (DEX) on alternating days. On the day of the third DEX injection, the left thoracic air sac of each bird was injected with sterile tryptose phosphate broth (TPB) or with TPB containing approximately 1 x 10(2), 1 x 10(3), 1 x 10(4), or 1 x 10(5) cfu of Escherichia coli. All mortalities and birds necropsied at 14 and 15 d postchallenge were scored for air sacculitis/pericarditis (AS) and turkey osteomyelitis complex (TOC). Cumulative mortality and AS score were both increased by either DEX treatment or E. coli. Although TOC incidence was significantly increased by the lowest titer of E. coli inoculation, increasing the number of bacteria inoculated did not increase TOC incidence due to increased mortality before TOC lesions developed. The DEX treatment by itself increased TOC incidence and there was a synergistic interaction between DEX treatment and E. coli on TOC incidence. Both DEX treatment and E. coli significantly decreased BW. Relative weights of liver, heart, and spleen were significantly increased by both E. coli and DEX, whereas both treatments significantly decreased relative weight of the bursa of Fabricius. The number of positive bacterial isolations from tissue and the heterophil to lymphocyte ratio were increased by both DEX treatment and E. coli challenge. These results suggest that stress-induced immunosuppression may be involved in the etiology of TOC, and that bacterial respiratory infection can lead to the development of TOC lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603351     DOI: 10.1093/ps/77.5.654

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  6 in total

1.  Technical note: fluorescein as an indicator of enteric mucosal barrier function in preruminant lambs.

Authors:  Audrey F Duff; Lisa R Bielke; Alejandro E Relling
Journal:  J Anim Sci       Date:  2020-07-01       Impact factor: 3.159

2.  Impact of dietary Mannan-oligosaccharide and β-Glucan supplementation on growth, histopathology, E-coli colonization and hepatic transcripts of TNF-α and NF- ϰB of broiler challenged with E. coli O78.

Authors:  Sabreen Ezzat Fadl; Ghada Ahmed El-Gammal; Osama Atia Sakr; Aly A B S Salah; Ayman Ali Atia; Abdelbary Mohammed Prince; Abdelhaleem Mohamed Hegazy
Journal:  BMC Vet Res       Date:  2020-06-19       Impact factor: 2.741

3.  Transcriptomic Analysis of Spleen Revealed Mechanism of Dexamethasone-Induced Immune Suppression in Chicks.

Authors:  Yujie Guo; Aru Su; Huihui Tian; Minxi Zhai; Wenting Li; Yadong Tian; Kui Li; Guirong Sun; Ruirui Jiang; Ruili Han; Fengbin Yan; Xiangtao Kang
Journal:  Genes (Basel)       Date:  2020-05-06       Impact factor: 4.096

4.  Bone circulatory disturbances in the development of spontaneous bacterial chondronecrosis with osteomyelitis: a translational model for the pathogenesis of femoral head necrosis.

Authors:  Robert F Wideman; Rhonda D Prisby
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-22       Impact factor: 5.555

5.  Mode of Action of Dietary Dexamethasone May Not Be Dependent Upon Microbial Mechanisms in Broilers.

Authors:  Audrey F Duff; Mikayla F A Baxter; B Danielle Graham; Billy M Hargis; Lisa R Bielke
Journal:  Microorganisms       Date:  2019-09-12

6.  Evaluation of in ovo Bacillus spp. based probiotic administration on horizontal transmission of virulent Escherichia coli in neonatal broiler chickens.

Authors:  M A Arreguin-Nava; B D Graham; B Adhikari; M Agnello; C M Selby; X Hernandez-Velasco; C N Vuong; B Solis-Cruz; D Hernandez-Patlan; J D Latorre; G Tellez; B M Hargis; G Tellez-Isaias
Journal:  Poult Sci       Date:  2019-12-01       Impact factor: 3.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.